ENDRA Life Sciences Inc.
NDRA
$4.87
$0.020.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.91M | 6.46M | 6.23M | 6.83M | 7.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.76M | 8.44M | 8.58M | 9.51M | 10.82M |
| Operating Income | -5.76M | -8.44M | -8.58M | -9.51M | -10.82M |
| Income Before Tax | -7.03M | -8.01M | -8.77M | -9.77M | -11.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.03 | -8.01 | -8.77 | -9.77 | -11.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.03M | -8.01M | -8.77M | -9.77M | -11.51M |
| EBIT | -5.76M | -8.44M | -8.58M | -9.51M | -10.82M |
| EBITDA | -5.72M | -8.39M | -8.53M | -9.46M | -10.77M |
| EPS Basic | -8.52 | -13.35 | -20.79 | -162.07 | -160.21 |
| Normalized Basic EPS | -5.33 | -11.91 | -16.56 | -104.86 | -103.70 |
| EPS Diluted | -8.52 | -13.35 | -20.79 | -162.07 | -160.21 |
| Normalized Diluted EPS | -5.33 | -11.91 | -16.56 | -104.86 | -103.70 |
| Average Basic Shares Outstanding | 3.15M | 2.58M | 2.06M | 1.36M | 802.00K |
| Average Diluted Shares Outstanding | 3.15M | 2.58M | 2.06M | 1.36M | 802.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |